Exact Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti Sells 3,207 Shares of Stock

Exact Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti sold 3,207 shares of the firm’s stock in a transaction on Friday, June 13th. The stock was sold at an average price of $53.20, for a total transaction of $170,612.40. Following the completion of the sale, the director now owns 72,759 shares in the company, valued at approximately $3,870,778.80. The trade was a 4.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Exact Sciences Stock Down 0.4%

Shares of NASDAQ:EXAS opened at $53.30 on Tuesday. The company’s fifty day moving average is $51.25 and its 200-day moving average is $51.98. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83. The company has a market capitalization of $10.05 billion, a PE ratio of -9.57 and a beta of 0.98.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $706.79 million during the quarter, compared to analysts’ expectations of $688.58 million. During the same period in the previous year, the business posted ($0.60) earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EXAS. Price T Rowe Associates Inc. MD raised its holdings in shares of Exact Sciences by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock valued at $323,669,000 after buying an additional 2,462,165 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Exact Sciences by 120.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock valued at $135,453,000 after buying an additional 1,707,287 shares during the last quarter. Capital World Investors raised its holdings in shares of Exact Sciences by 10.7% in the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock valued at $985,439,000 after buying an additional 1,696,321 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of Exact Sciences by 107.7% in the fourth quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock valued at $164,037,000 after buying an additional 1,513,873 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Exact Sciences in the first quarter valued at about $45,334,000. 88.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Mizuho assumed coverage on shares of Exact Sciences in a research note on Thursday, April 10th. They issued an “outperform” rating and a $60.00 price objective on the stock. Bank of America decreased their price target on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Royal Bank of Canada lifted their price target on shares of Exact Sciences from $52.00 to $54.00 and gave the stock a “sector perform” rating in a research note on Friday, May 2nd. Piper Sandler decreased their price target on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, Scotiabank lifted their price target on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 24th. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $70.90.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.